Virtu Financial LLC Takes Position in Cytokinetics, Incorporated (NASDAQ:CYTK)

Virtu Financial LLC bought a new stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 6,433 shares of the biopharmaceutical company's stock, valued at approximately $303,000.

A number of other large investors also recently made changes to their positions in CYTK. Jones Financial Companies Lllp grew its position in Cytokinetics by 189.8% during the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 374 shares in the last quarter. Centricity Wealth Management LLC acquired a new stake in shares of Cytokinetics during the 4th quarter valued at $29,000. AlphaQuest LLC grew its holdings in shares of Cytokinetics by 113,500.0% during the 4th quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 1,135 shares in the last quarter. J.Safra Asset Management Corp increased its stake in shares of Cytokinetics by 62.1% in the fourth quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company's stock worth $83,000 after acquiring an additional 671 shares during the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Cytokinetics by 85.8% during the fourth quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 842 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have weighed in on CYTK shares. Morgan Stanley set a $67.00 target price on Cytokinetics in a research report on Friday, March 7th. Royal Bank of Canada raised their price objective on shares of Cytokinetics from $80.00 to $82.00 and gave the company an "outperform" rating in a research report on Wednesday, December 18th. HC Wainwright reissued a "buy" rating and issued a $120.00 target price on shares of Cytokinetics in a research report on Friday, February 28th. Evercore ISI upgraded shares of Cytokinetics to a "strong-buy" rating in a report on Friday, February 7th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $78.00 price objective on shares of Cytokinetics in a report on Friday, February 7th. Two investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $82.00.

Remove Ads

Insider Buying and Selling

In related news, EVP Fady Ibraham Malik sold 2,000 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $45.92, for a total value of $91,840.00. Following the completion of the transaction, the executive vice president now directly owns 116,071 shares of the company's stock, valued at $5,329,980.32. This trade represents a 1.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert I. Blum sold 15,000 shares of the business's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $40.75, for a total transaction of $611,250.00. Following the completion of the sale, the chief executive officer now directly owns 427,629 shares in the company, valued at $17,425,881.75. This trade represents a 3.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 58,834 shares of company stock valued at $2,560,525 over the last three months. 3.40% of the stock is owned by corporate insiders.

Cytokinetics Stock Performance

Shares of CYTK traded down $2.69 during mid-day trading on Tuesday, hitting $37.50. The company's stock had a trading volume of 2,503,922 shares, compared to its average volume of 1,510,812. Cytokinetics, Incorporated has a one year low of $37.49 and a one year high of $75.71. The stock's 50-day moving average is $45.47 and its two-hundred day moving average is $49.29. The firm has a market capitalization of $4.44 billion, a PE ratio of -6.97 and a beta of 0.95. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.29) by $0.03. The company had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.26 million. As a group, sell-side analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.